{"id":26055,"date":"2022-07-18T16:59:13","date_gmt":"2022-07-18T15:59:13","guid":{"rendered":"https:\/\/ppr-antibioresistance.inserm.fr\/?p=26055"},"modified":"2022-07-18T16:59:17","modified_gmt":"2022-07-18T15:59:17","slug":"cdc-covid-19-u-s-impact-on-antimicrobial-resistance-special-report-2022","status":"publish","type":"post","link":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/cdc-covid-19-u-s-impact-on-antimicrobial-resistance-special-report-2022\/","title":{"rendered":"CDC COVID-19: U.S. Impact on Antimicrobial Resistance, Special Report 2022"},"content":{"rendered":"\n<p>Article published on the <a href=\"https:\/\/www.cdc.gov\/drugresistance\/covid19.html\" target=\"_blank\" rel=\"noreferrer noopener\">CDC website<\/a><\/p>\n\n\n\n<p> <\/p>\n\n\n\n<p>The U.S. lost progress combating antimicrobial resistance in 2020 due, in large part, to effects of the COVID-19 pandemic. The CDC&nbsp;<a href=\"https:\/\/www.cdc.gov\/drugresistance\/pdf\/covid19-impact-report-508.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">COVID-19: U.S. Impact on Antimicrobial Resistance, Special Report 2022&nbsp;[PDF \u2013 44 pages]<\/a>, concluded that the threat of antimicrobial-resistant infections is not only still present but has gotten worse.<\/p>\n\n\n\n<p>During the first year of the pandemic, more than 29,400 people died from antimicrobial-resistant infections commonly associated with healthcare. Of these, nearly 40% of the people got the infection while they were in the hospital.<\/p>\n\n\n\n<p>The total national burden of deaths from antimicrobial resistance may be much higher, but data gaps caused by the pandemic hinder that analysis. CDC is missing data for nine of the 18 pathogens listed in its\u00a0<a href=\"https:\/\/www.cdc.gov\/drugresistance\/biggest-threats.html\" target=\"_blank\" rel=\"noreferrer noopener\">2019 AR Threats Report.<\/a>\u00a0CDC\u2019s 2019 estimates are still the strongest data to show the U.S. burden of antimicrobial resistance\u2014at least 2.8 million antimicrobial-resistant infections continue to occur in the U.S. each year and more than 35,000 people die as a result.<\/p>\n\n\n\n<p>In the 2019 AR Threats Report,\u00a0<a href=\"https:\/\/www.cdc.gov\/drugresistance\/biggest-threats.html\" target=\"_blank\" rel=\"noreferrer noopener\">CDC reported<\/a>\u00a0that nationwide investments in prevention drove down deaths from antimicrobial-resistant infections by 18% from 2012 through 2017. CDC data show these reductions continued until 2020. But the pandemic resulted in more resistant infections, increased antibiotic use, and less data and prevention actions.<\/p>\n\n\n\n<p>This setback can and must be temporary. If properly resourced, the U.S. can continue to build resilient public health and healthcare systems to keep our nation safe from antimicrobial resistance.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><a><\/a>COVID-19 Impact on Healthcare Facilities &amp; Community Settings<\/h3>\n\n\n\n<p>On This Page<\/p>\n\n\n\n<ul><li><a href=\"https:\/\/www.cdc.gov\/drugresistance\/covid19.html#anchor_1656420501815\" target=\"_blank\" rel=\"noreferrer noopener\">COVID-19 Impact on Healthcare Facilities &amp; Community Settings<\/a><\/li><li><a href=\"https:\/\/www.cdc.gov\/drugresistance\/covid19.html#anchor_1656420732861\" target=\"_blank\" rel=\"noreferrer noopener\">COVID-19 Impact on Five Core Actions to Combat Resistance\u00a0<\/a><\/li><li><a href=\"https:\/\/www.cdc.gov\/drugresistance\/covid19.html#anchor_1656421934582\" target=\"_blank\" rel=\"noreferrer noopener\">Fact Sheets, Graphics, &amp; Videos<\/a><\/li><li><a href=\"https:\/\/www.cdc.gov\/drugresistance\/covid19.html#anchor_1656422781814\" target=\"_blank\" rel=\"noreferrer noopener\">More Information<\/a><\/li><\/ul>\n\n\n\n<p>COVID-19 Impact Report<\/p>\n\n\n\n<ul><li><a class=\"\" href=\"https:\/\/www.cdc.gov\/drugresistance\/pdf\/covid19-impact-report-508.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">2022 Special Report: COVID-19 U.S. Impact on AR&nbsp;[PDF &#8211; 44 pages]<\/a><\/li><\/ul>\n\n\n\n<p>U.S.\u00a0<a href=\"https:\/\/www.cdc.gov\/drugresistance\/healthcare-facilities.html\" target=\"_blank\" rel=\"noreferrer noopener\">healthcare facilities<\/a>\u00a0saw more healthcare-associated, antimicrobial-resistant infections, especially in hospitals. Hospitals treated sicker patients who required more frequent and longer use of medical devices like catheters and ventilators. Hospitals also experienced personal protective equipment supply challenges, staffing shortages, and longer patient visits.<\/p>\n\n\n\n<ul><li>Resistant hospital-onset infections and deaths both increased at least 15% from 2019 to 2020 among seven pathogens.<\/li><li>A\u00a0<a href=\"https:\/\/www.cdc.gov\/hai\/data\/portal\/covid-impact-hai.html\" target=\"_blank\" rel=\"noreferrer noopener\">2021 CDC analysis<\/a>\u00a0reported that, after years of steady reductions in healthcare-associated infections (HAIs), U.S. hospitals saw significantly higher rates for four out of six types of HAIs in 2020. Many of these HAIs are resistant to antibiotics.<strong>\u00a0<\/strong><\/li><li>Antifungal-resistant threats rose in 2020, too, including\u00a0<em>Candida auris<\/em>\u2014which increased 60% overall\u2014and\u00a0<em>Candida<\/em>\u00a0species (excluding\u00a0<em>Candida auris)<\/em>, with a 26% increase in infections in hospitals.<\/li><\/ul>\n\n\n\n<p>In\u00a0<a href=\"https:\/\/www.cdc.gov\/drugresistance\/communities.html\" target=\"_blank\" rel=\"noreferrer noopener\">communities<\/a>, CDC has limited data for the spread of antimicrobial-resistant pathogens, like\u00a0<a href=\"https:\/\/www.cdc.gov\/std\/gonorrhea\/arg\/default.htm\" target=\"_blank\" rel=\"noreferrer noopener\">drug-resistant gonorrhea<\/a>\u00a0and foodborne germs.<\/p>\n\n\n\n<ul><li>Public health personnel nationwide were diverted to the pandemic response and people (potential patients) had reduced access to care and testing services.<\/li><li>Many clinics and healthcare facilities limited services, served fewer patients, or closed their doors entirely in the face of challenges from COVID-19.<\/li><li>Before the pandemic,\u00a0<a href=\"https:\/\/www.cdc.gov\/drugresistance\/biggest-threats.html\" target=\"_blank\" rel=\"noreferrer noopener\">CDC data<\/a>\u00a0showed many resistant infections often found in the community were increasing (2012-2017). CDC is concerned that resistant infections continued to spread in communities undetected and untreated in 2020.<\/li><\/ul>\n\n\n\n<p>Many of the nation\u2019s efforts to combat antimicrobial resistance also helped prevent the spread of COVID-19.This includes\u00a0<a href=\"https:\/\/www.cdc.gov\/drugresistance\/solutions-initiative\/index.html\" target=\"_blank\" rel=\"noreferrer noopener\">CDC investments<\/a>\u00a0in infection prevention and control, training, surveillance, and public health personnel, such as:<\/p>\n\n\n\n<ul><li>Providing COVID-19 testing and identifying antimicrobial-resistant outbreaks through CDC\u2019s\u00a0<a href=\"https:\/\/www.cdc.gov\/drugresistance\/laboratories.html\" target=\"_blank\" rel=\"noreferrer noopener\">Antimicrobial Resistance Laboratory Network<\/a>\u00a0(AR Lab Network) in 50 states and several cities\/territories<\/li><li>Supporting experts in infection prevention and control, including healthcare training programs like\u00a0<a href=\"https:\/\/www.cdc.gov\/infectioncontrol\/projectfirstline\/index.html\" target=\"_blank\" rel=\"noreferrer noopener\">Project Firstline<\/a>\u00a0to help stop the spread of pathogens<\/li><li>Developing and implementing\u00a0<a href=\"https:\/\/www.cdc.gov\/antibiotic-use\/materials-references\/index.html\" target=\"_blank\" rel=\"noreferrer noopener\">antibiotic use tools<\/a>\u00a0for frontline workers<\/li><li>Working with partners and\u00a0<a href=\"https:\/\/www.cdc.gov\/drugresistance\/solutions-initiative\/funding.html\" target=\"_blank\" rel=\"noreferrer noopener\">supporting projects<\/a>\u00a0to improve clinical and public health outcomes and control emerging infectious disease threats, such as antimicrobial resistance and COVID-19<\/li><\/ul>\n\n\n\n<p>Find more CDC-led antimicrobial resistance and COVID-19&nbsp;<a href=\"https:\/\/arinvestments.cdc.gov\/PDFDocs\/ARfundingHelpsCovid.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">public health activities&nbsp;[PDF \u2013 2 pages]<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Article published on the CDC website The U.S. lost progress combating antimicrobial resistance in 2020 due, in large part, to effects of the COVID-19 pandemic. The CDC&nbsp;COVID-19: U.S. Impact on Antimicrobial Resistance, Special Report 2022&nbsp;[PDF \u2013 44 pages], concluded that the threat of antimicrobial-resistant infections is not only still present but has gotten worse. During [&hellip;]<\/p>\n","protected":false},"author":139,"featured_media":26061,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[37],"tags":[],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>CDC COVID-19: U.S. Impact on Antimicrobial Resistance, Special Report 2022 - French\u00a0National ANTIBIOTIC RESISTANCE Portal<\/title>\n<meta name=\"description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l&#039;Antibior\u00e9sistance en France et \u00e0 l&#039;international.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/cdc-covid-19-u-s-impact-on-antimicrobial-resistance-special-report-2022\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CDC COVID-19: U.S. Impact on Antimicrobial Resistance, Special Report 2022 - French\u00a0National ANTIBIOTIC RESISTANCE Portal\" \/>\n<meta property=\"og:description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l&#039;Antibior\u00e9sistance en France et \u00e0 l&#039;international.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/cdc-covid-19-u-s-impact-on-antimicrobial-resistance-special-report-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"French\u00a0National ANTIBIOTIC RESISTANCE Portal\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-18T15:59:13+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-07-18T15:59:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/07\/Medecin-covid.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"623\" \/>\n\t<meta property=\"og:image:height\" content=\"610\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"\u00c9milie Noguez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"\u00c9milie Noguez\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/cdc-covid-19-u-s-impact-on-antimicrobial-resistance-special-report-2022\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/cdc-covid-19-u-s-impact-on-antimicrobial-resistance-special-report-2022\/\"},\"author\":{\"name\":\"\u00c9milie Noguez\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3\"},\"headline\":\"CDC COVID-19: U.S. Impact on Antimicrobial Resistance, Special Report 2022\",\"datePublished\":\"2022-07-18T15:59:13+00:00\",\"dateModified\":\"2022-07-18T15:59:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/cdc-covid-19-u-s-impact-on-antimicrobial-resistance-special-report-2022\/\"},\"wordCount\":642,\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/cdc-covid-19-u-s-impact-on-antimicrobial-resistance-special-report-2022\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/07\/Medecin-covid.jpg\",\"articleSection\":[\"Bilans, rapports et recommandations\"],\"inLanguage\":\"en-GB\"},{\"@type\":[\"WebPage\",\"ItemPage\"],\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/cdc-covid-19-u-s-impact-on-antimicrobial-resistance-special-report-2022\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/cdc-covid-19-u-s-impact-on-antimicrobial-resistance-special-report-2022\/\",\"name\":\"CDC COVID-19: U.S. Impact on Antimicrobial Resistance, Special Report 2022 - French\u00a0National ANTIBIOTIC RESISTANCE Portal\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/cdc-covid-19-u-s-impact-on-antimicrobial-resistance-special-report-2022\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/cdc-covid-19-u-s-impact-on-antimicrobial-resistance-special-report-2022\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/07\/Medecin-covid.jpg\",\"datePublished\":\"2022-07-18T15:59:13+00:00\",\"dateModified\":\"2022-07-18T15:59:17+00:00\",\"description\":\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.\",\"breadcrumb\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/cdc-covid-19-u-s-impact-on-antimicrobial-resistance-special-report-2022\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/cdc-covid-19-u-s-impact-on-antimicrobial-resistance-special-report-2022\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/cdc-covid-19-u-s-impact-on-antimicrobial-resistance-special-report-2022\/#primaryimage\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/07\/Medecin-covid.jpg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/07\/Medecin-covid.jpg\",\"width\":623,\"height\":610,\"caption\":\"Cr\u00e9dit : Pixabay\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/cdc-covid-19-u-s-impact-on-antimicrobial-resistance-special-report-2022\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Practical info &amp; communications\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Reviews, reports and recommendations\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/reviews-reports-recommendations\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"CDC COVID-19: U.S. Impact on Antimicrobial Resistance, Special Report 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/\",\"name\":\"French\u00a0National ANTIBIOTIC RESISTANCE Portal\",\"description\":\"INSERM - From science to health\",\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization\",\"name\":\"Inserm\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"width\":1,\"height\":1,\"caption\":\"Inserm\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3\",\"name\":\"\u00c9milie Noguez\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CDC COVID-19: U.S. Impact on Antimicrobial Resistance, Special Report 2022 - French\u00a0National ANTIBIOTIC RESISTANCE Portal","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/cdc-covid-19-u-s-impact-on-antimicrobial-resistance-special-report-2022\/","og_locale":"en_GB","og_type":"article","og_title":"CDC COVID-19: U.S. Impact on Antimicrobial Resistance, Special Report 2022 - French\u00a0National ANTIBIOTIC RESISTANCE Portal","og_description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","og_url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/cdc-covid-19-u-s-impact-on-antimicrobial-resistance-special-report-2022\/","og_site_name":"French\u00a0National ANTIBIOTIC RESISTANCE Portal","article_published_time":"2022-07-18T15:59:13+00:00","article_modified_time":"2022-07-18T15:59:17+00:00","og_image":[{"width":623,"height":610,"url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/07\/Medecin-covid.jpg","type":"image\/jpeg"}],"author":"\u00c9milie Noguez","twitter_card":"summary_large_image","twitter_misc":{"Written by":"\u00c9milie Noguez","Estimated reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/cdc-covid-19-u-s-impact-on-antimicrobial-resistance-special-report-2022\/#article","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/cdc-covid-19-u-s-impact-on-antimicrobial-resistance-special-report-2022\/"},"author":{"name":"\u00c9milie Noguez","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3"},"headline":"CDC COVID-19: U.S. Impact on Antimicrobial Resistance, Special Report 2022","datePublished":"2022-07-18T15:59:13+00:00","dateModified":"2022-07-18T15:59:17+00:00","mainEntityOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/cdc-covid-19-u-s-impact-on-antimicrobial-resistance-special-report-2022\/"},"wordCount":642,"publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/cdc-covid-19-u-s-impact-on-antimicrobial-resistance-special-report-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/07\/Medecin-covid.jpg","articleSection":["Bilans, rapports et recommandations"],"inLanguage":"en-GB"},{"@type":["WebPage","ItemPage"],"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/cdc-covid-19-u-s-impact-on-antimicrobial-resistance-special-report-2022\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/cdc-covid-19-u-s-impact-on-antimicrobial-resistance-special-report-2022\/","name":"CDC COVID-19: U.S. Impact on Antimicrobial Resistance, Special Report 2022 - French\u00a0National ANTIBIOTIC RESISTANCE Portal","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/cdc-covid-19-u-s-impact-on-antimicrobial-resistance-special-report-2022\/#primaryimage"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/cdc-covid-19-u-s-impact-on-antimicrobial-resistance-special-report-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/07\/Medecin-covid.jpg","datePublished":"2022-07-18T15:59:13+00:00","dateModified":"2022-07-18T15:59:17+00:00","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","breadcrumb":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/cdc-covid-19-u-s-impact-on-antimicrobial-resistance-special-report-2022\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/cdc-covid-19-u-s-impact-on-antimicrobial-resistance-special-report-2022\/"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/cdc-covid-19-u-s-impact-on-antimicrobial-resistance-special-report-2022\/#primaryimage","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/07\/Medecin-covid.jpg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/07\/Medecin-covid.jpg","width":623,"height":610,"caption":"Cr\u00e9dit : Pixabay"},{"@type":"BreadcrumbList","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/cdc-covid-19-u-s-impact-on-antimicrobial-resistance-special-report-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/"},{"@type":"ListItem","position":2,"name":"Practical info &amp; communications","item":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/"},{"@type":"ListItem","position":3,"name":"Reviews, reports and recommendations","item":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/reviews-reports-recommendations\/"},{"@type":"ListItem","position":4,"name":"CDC COVID-19: U.S. Impact on Antimicrobial Resistance, Special Report 2022"}]},{"@type":"WebSite","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website","url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/","name":"French\u00a0National ANTIBIOTIC RESISTANCE Portal","description":"INSERM - From science to health","publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-GB"},{"@type":"Organization","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization","name":"Inserm","url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","width":1,"height":1,"caption":"Inserm"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3","name":"\u00c9milie Noguez"}]}},"publishpress_future_action":{"enabled":false,"date":"2026-04-15 16:30:15","action":"change-status","newStatus":"private","terms":[],"taxonomy":"category"},"post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/posts\/26055"}],"collection":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/users\/139"}],"replies":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/comments?post=26055"}],"version-history":[{"count":6,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/posts\/26055\/revisions"}],"predecessor-version":[{"id":26071,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/posts\/26055\/revisions\/26071"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/media\/26061"}],"wp:attachment":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/media?parent=26055"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/categories?post=26055"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/tags?post=26055"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}